Back to today’s briefing

Story perspectives

Marken Enhances Supply Chain for Time-Sensitive Therapies

4/3/2026

37 6 Full Breakdown

Summary

Story summary

Marken, a subsidiary of UPS, is adapting its supply chain strategies for advanced therapies in clinical trials.
As of 2018, over 1,000 active trials for regenerative medicines have emerged, with cancer studies increasing.
Advanced therapies like CAR-T require precise, time-sensitive logistics due to their sensitivity.
Marken has a proven track record, including Phase III trial risk assessments and timely processing of patient cells.

1 of 1

Story summary

Marken, a subsidiary of UPS, is adapting its supply chain strategies for advanced therapies in clinical trials.
As of 2018, over 1,000 active trials for regenerative medicines have emerged, with cancer studies increasing.
Advanced therapies like CAR-T require precise, time-sensitive logistics due to their sensitivity.
Marken has a proven track record, including Phase III trial risk assessments and timely processing of patient cells.